Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
The NewYork-Presbyterian Weill Cornell Transplant program, in cooperation with the Rogosin Institute, was the first kidney transplant program established in New York State, now more than five decades ago.
Since that time, over 5,000 kidney transplants have been performed. With approximately 200 kidney transplants performed each year since 2006, our program is among the largest in the country offering the very latest transplant management protocols and surgical interventions.
Our transplant center’s patient and graft survival rates are excellent, which is especially notable given our diverse and often complicated patient population. Transplant outcomes are calculated by the Scientific Registry of Transplant Recipients (SRTR) based on the mix of recipient and donor characteristics at our center compared with experience with similar patients throughout the country.
Molecular tools developed at Weill Cornell Medicine allow us, for the first time in the history of kidney transplantation, to individualize the medication regimen used to suppress the immune system. At the same time, these tools reduce the amount of exposure to these medications.
Since 2001, approximately 75 percent of our kidney transplant patients have received a steroid-sparing medication regimen and over 2,000 transplanted patients are completely off of steroids.